Connexin Hemichannels in Astrocytes: Role in CNS Disorders

LingYan Xing1†, Tuo Yang2†, ShuSen Cui2* and Gang Chen1,3*

1 Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China, 2 Department of Hand Surgery, China-Japan Union Hospital of Jilin University, Changchun, China, 3 Department of Anesthesiology, Affiliated Hospital of Nantong University, Nantong, China

In the central nervous system (CNS), astrocytes form networks interconnected by gap junctions made from connexins of the subtypes Cx30 and Cx43. When unopposed by an adjoining hemichannel, astrocytic connexins can act as hemichannels to control the release of small molecules such as ATP and glutamate into the extracellular space. Accruing evidence indicates that astrocytic connexins are crucial for the coordination and maintenance of physiologic CNS activity. Here we provide an update on the role of astrocytic connexins in neurodegenerative disorders, glioma, and ischemia. In addition, we address the regulation of Cx43 in chronic pain.

Keywords: astrocyte, connexin 43, Alzheimer’s disease, glioma, ischemia, neuropathic pain

INTRODUCTION

As the most abundant cells in the central nervous system, astrocytes are critical for synaptic transmission and homeostasis maintenance. Astrocyte dysfunction has been associated with many neurological disorders, including but not limited to neurodegenerative diseases, gliomas, and ischemia (Verkhratsky et al., 2010; Yang et al., 2013; Hirayama and Koizumi, 2018). Over the last two decades, accumulating evidence has shown that astrocytes are also key mediators in pain development and maintenance (Ji et al., 2013).

Astrocytes in the CNS form a highly interconnected network via gap junctions or hemichannels. Each connexin hemichannel consists of six protein subunits termed connexins, which belong to a protein family encoded by 20–21 genes in mammals (Scott et al., 2012). An individual subunit possesses four alpha-helical transmembrane domains, connected by two extracellular loops and one intracellular loop, with cytoplasmic carboxyl and amine terminals (Bennett et al., 2016). When one hemichannel docks to its counterpart on the apposed cells, a gap junction is formed. Gap junctions of astrocytes allow rapid intercellular exchange of ions and metabolites, which is critical for K+ and glutamate buffering, calcium wave propagation, and synaptic plasticity (Li et al., 2014; Lapato and Tiwari-Woodruff, 2018). Unpaired connexins can act as hemichannels, which are responsible for the release of gliotransmitters, including ATP, glutamate, nicotinamide adenine dinucleotide (NAD), and D-serine to the extracellular milieu (Saez et al., 2003; Retamal et al., 2014). This offers a new exchange route between neurons and glia.

Accruing evidence suggests that connexin hemichannels can open at both physiological and pathological conditions (Saez et al., 2003). The opening of hemichannels is highly dynamic and can be controlled by multiple regulators. Lower or higher intercellular Ca2+ can increase the opening probability of hemichannels (Decrock et al., 2011). In addition, pathological conditions, such as oxidative stress, lower pH, mechanical stimulation, and inflammation can significantly enhance the hemichannel opening (Johansen et al., 2011; Batra et al., 2014; Castellano and Eugenin, 2014;
Retamal et al., 2015). The uncontrolled opening of hemichannels can lead to cell damage and homeostatic imbalance (Orellana, 2016). It is accepted that excessive release of ATP and glutamate or overload of intracellular free Ca\(^{2+}\) are toxic to neighboring cells or trigger secondary damages to distant cells (Takeuchi et al., 2006; Orellana et al., 2011). Of note, dysregulation of hemichannel permeability can also induce excessive influx of Na\(^{+}\) and Cl\(^{-}\), leading to osmotic and ionic imbalance (Orellana et al., 2016). In astrocytes, the predominant connexins are connexin 43 (Cx43), though Cx26 and Cx30 are also detectable (Rash et al., 2001a,b). This review will focus on the role of astrocytic Cx43 in the regulation of CNS disorders (Table 1, Figure 1). Furthermore, we also discuss an emerging role of astrocyte Cx43 in chronic pain (Table 2).

**Cx43 IN NEURODEGENERATIVE DISEASES**

Alzheimer’s disease (AD), a representative CNS neurodegenerative disease characterized by plaques and tangles in the brain (Ballard et al., 2011), is the leading cause of dementia worldwide. Until recently, the role of astrocytes in AD has been appreciated, though astrocytic modification was discovered in AD decades ago (Nagy et al., 1996; Rodríguez et al., 2010). Astrogliosis and β-amyloid(Aβ) plaque, two prominent pathologic features of AD, are both highly associated with astrocytic connexins, which offer a novel pathological mechanism and a potential therapeutic target for AD (Yi et al., 2017b). Altered expression of astrocytic connexins have been observed in the brains of both AD patients and mice (Nagy et al., 1996; Mei et al., 2010), though the mechanisms by which connexins expression is changed, remain controversial. For example, the expression of Cx43 in astrocytic gap junctions of AD patients is upregulated in the cortical regions with Aβ plaques, and some plaques corresponded exactly to the potentiated Cx43 immunoreactive sites (Nagy et al., 1996). In older APP/PS1 mice, a murine model of familial AD, an increase of Cx43 and Cx30 immunoreactivity was found in 60–70% Aβ plaques of reactive astrocytes. However, a decrease in the expression of Cx43 and Cx30 was also found in a few newly formed plaques (<10%) (Mei et al., 2010). This discrepancy indicates that the alteration of Cx43 expression in AD depends on the amyloid pathology and local inflammatory status of the plaque sites (Koulakoff et al., 2012). The increase in Cx43 expression promotes astrogliosis and further alters astroglial channel function and the pathologic process of AD.

Studies have been performed to investigate the role of Cx43 in AD, either as gap junction channels or hemichannels. Interestingly, the reactive astrogliosis does not affect astrogial gap junctional communication in APP/PS1 mice (Yi et al., 2017b). Hemichannels in astrocytes, however, can be activated during the pathologic process of AD and are critical for the neuronal damage (Orellana et al., 2011). The activated hemichannels increase the release of ATP and glutamate from astrocytes around the amyloid plaques, leading to overload of neuronal Ca\(^{2+}\), synaptic depression (Pascual, 2005), and final neuronal damage (Yi et al., 2016). Neuronal damages in the process could be alleviated by Cx43 hemichannel blocker boldine or cannabinoids (Gajardo-Gómez et al., 2017; Yi et al., 2017a). Additionally, in APP/PS1 mice, a specific deletion of astroglial Cx43 could significantly reduce astrogliosis and increase synapse numbers, though it had no effects on amyloid plaque formation or inflammatory response (Ren et al., 2018). These results indicate that Cx43 could be a novel therapeutic target for AD.

As the second most common chronic neurodegenerative disorder in the CNS, Parkinson’s disease (PD) possesses reactive astrocytes in the substantia nigra (Fernandez, 2012; Cabezas et al., 2014). Rotenone is a common neurotoxic substance used for generating PD experimental models. In both rotenone-treated rats and in vitro astrocytes, levels of both total Cx43 and phosphorylated Cx43 were elevated (Wang Y. et al., 2013). Additionally, gastrodin from a Chinese herbal medicine can ameliorate PD by downregulating Cx43 (Wang Y. et al., 2013). Cx43 expression was also found upregulated in patients with amyotrophic lateral sclerosis (ALS) or related models (Almad et al., 2016). This upregulated Cx43 expression led to elevated hemichannel activity, enhanced gap junction coupling and increased intracellular Ca\(^{2+}\) concentration, which contributed to motor neuron toxicity. Furthermore, it was conferred that Cx43 blocker or Cx43 hemichannel blocker provided protection against this neuron toxicity (Almad et al., 2016).

Overall, the role of astrocytes as well as astrocytic connexins has attracted more attention in the field of neurodegenerative diseases in recent years, due to their critical role in gliosis, inflammation, and neuronal damage (Freitas-Andrade and Naus, 2016). Here we pose several questions and perspectives for further study. First, in-depth studies may be needed to apply and clarify the targets of these interventions, for example, R76W mutant which specifically block gap junction channels (Xu et al., 2015), Gap19 (a specific Cx43 hemichannel blocker) (Wang N. et al., 2013) and non-selective peptides. Second, the discrepancy of Cx43 immunoreactivity in neurodegenerative diseases was found in a previous study (Mei et al., 2010), which may lead us to test how Cx43 works in a time-dependent manner.

**Cx43 IN GLIOMA**

Glioblastoma (GBM), a representative type of malignant glioma, is the most common and aggressive CNS malignant tumor (Sontheimer, 2015). Both the expression changes of Cx43 and its role in glioma progression are controversial, which may be attributed to high heterogeneity of this tumor (Sin et al., 2012). The expression of Cx43 varies with grades, stages, and locations of tumors. For example, Cx43 generally exhibits a lower expression in low-grade ones (Sin et al., 2016). As a conventional therapeutic strategy, surgical resection supplemented with chemotherapy and radiotherapy confers a poor prognosis in patients with gliomas (Stupp et al., 2005). This poor prognosis is mainly caused by the resistance to the chemotherapeutic alkylating agents such as temozolomide (TMZ), and the invasive nature of the tumor cells (Sin et al., 2012, 2016; Wang et al., 2018).
### TABLE 1 | Cx43 in the regulation of CNS disorders.

| Diseases and models | Cx43 expression changes | Manipulations and drugs | Target channel | Mechanism | Outcomes | Reference |
|---------------------|--------------------------|-------------------------|----------------|-----------|----------|-----------|
| AD                  | APP/PS1/Gfap-Cx43 KO mice | ↑                       | Astrocyte Cx43 KO | HC and GJC | APPswe/PS1dE9 + Gfap-Cx43 KO | ↑cognitive function | Ren et al., 2018 |
|                     |                          |                        |                |           |          |           |
|                     | APP/PS1/Gfap-Cx43 KO mice | ↑                       | Astrocyte Cx43 KO | HC and GJC | APPswe/PS1dE9 + Gfap-Cx43 KO | ↓astrogliosis | Yi et al., 2016 |
|                     |                          |                        |                |           |          |           |
|                     | APPswe/PS1dE9 mice       | ↑                       | boldine         | HC         | HC blockade | ↓neuronal damages | Yi et al., 2017a |
|                     |                          |                        |                |           |          |           |
|                     | Astrocytes and acute hippocampal slices treated with the active fragment of Aβ (in vitro) | ↑ | carbenoxolone | GJC | GJC blockade | ↑protective effects of ischemic preconditioning | Gajardo-Gómez et al., 2017 |
| Cerebral ischemia   | Astrocyte from Wistar rats | ↑                       | Cx43 mimetic peptides Gap26 and Gap27 | HC | Extracellular loop peptides | ↓cerebral infarct volume | Ma et al., 2018 |
|                     |                          |                        |                |           |          |           |
|                     | Neonatal SD rats         | ↑                       | Cx43 mimetic peptide5 | HC | Extracellular loop peptides | ↑dye leak (in vivo) | Li et al., 2015 |
|                     |                          |                        |                |           |          |           |
|                     | Retinal ischemia-reperfusion | ↑                       | Cx43 mimetic peptide | HC | Extracellular loop peptides | ↑retinal ganglion cell survival (in vitro) | Danesh-Meyer et al., 2012 |
|                     |                          |                        |                |           |          |           |
|                     | Glioma (glioblastoma)    | ↓, as the glioma grade increases | Cx43 KO and Cx43 truncated | HC and GJC | Gfap:Cre+Cx43fl/fl; C-terminal truncation at amino acid 258 | ↑glioma invasion | Sin et al., 2016 |
|                     |                          |                        |                |           |          |           |
|                     | GBM cells (in vitro)     | ↑                       | Cx43 siRNA      | HC and GJC | RNA interference | ↓TMZ resistance | Munoz et al., 2014 |
|                     |                          |                        |                |           |          |           |
|                     | BALB/c nude mice injected with LN229 human GBM stem cells | ↑ | αCT1 | HC | Cx43 C-terminus mimetic peptide | ↓TMZ resistance | Murphy et al., 2016 |
| Myocardial ischemia | Intact heart of rats     | —                       | Cx43 mimetic peptide Gap26 | HC | Extracellular loop peptides | ↑protection against myocardial ischemia-reperfusion injury | Hawat et al., 2010 |
| Amyotrophic Lateral Sclerosis | SOD1 mice and SOD1<sup>G93A</sup> mice | ↑ | Cx43 mimetic peptide Gap26 | HC | Extracellular loop peptides | ↑motor neurons survive | Almad et al., 2016 |

↑ denotes upregulation; ↓ denotes downregulation; — denotes data unavailable.
TABLE 2 | Expression changes of Cx43 in different pain models.

| Pain models and species | Cx43 expression changes | Manipulations and drugs | Target channel | Mechanism | Effects on pain | Reference |
|-------------------------|-------------------------|-------------------------|----------------|-----------|----------------|-----------|
| Spinal cord injury, mouse | ↑ | Cx43^{−/−}/Cx30^{−/−}, double knockout | HC and GJC | Cx30-KO + Gfap:Cre Cx43^{fl/fl} | ↓heat hyperalgiesia and mechanical allodynia | Chen et al., 2012 |
| Spinal cord injury (thoracic spinal cord hemisection), mouse | ↑ | Intrathecal injection of fluorocitrate and carbeneoxoline and Gap26 | HC and GJC | astrocyte metabolic inhibitor; gap junction/hemichannel blocker; Cx43 extracellular loop peptides | ↓SCI-induced bilateral below-level mechanical allodynia | Choi et al., 2016 |
| Spinal cord contusion, rat | ↑ | Intraperitoneal injection of Peptide6 | HC | Cx43 extracellular loop peptides | ↓PSNL-induced mechanical hypersensitivity | Morioka et al., 2015 |
| Chronic constriction injury (CCI) of the sciatic nerves, mouse | ↑ | Intrathecal injection of CBX, Gap26 or Gap27, astroglial toxin pretreatment of astrocytes, or Cx43 siRNA | HC and GJC | GJC blockade; Cx43 extracellular loop peptides; RNA interference | ↓mechanical allodynia | Chen et al., 2014 |
| CCI, mouse | ↑ | — | — | — | — | Neumann et al., 2015 |
| Spinal nerve ligation (SNL), rat | ↓ | Intrathecal Cx43 siRNA | HC and GJC | RNA interference | ↓mechanical hypersensitivity | Xu et al., 2014 |
| Spinal nerve ligation (SNL), rat | ↑ | Intrathecal CORM-2 administration | HC | Release CO as HC inhibitor | ↓hyperalgiesia and allodynia | Wang and Sun, 2017 |
| Partial sciatic nerve ligation (PSNL), mouse | ↓ | Intrathecal injection of an adenovirus vector expressing Cx43 | HC and GJC | RNA interference | ↓PSNL-induced mechanical hypersensitivity | Wang et al., 2018 |
| PSNL, mouse | ↓ | Intrathecal injection of lycopene | HC and GJC | Reversed TNF-induced downregulation of Cx43 expression | ↓mechanical hypersensitivity | Zhang et al., 2016 |
| Inferior alveolar nerve injury, rat | ↑ | Administration of Gap27 in the trigeminal ganglion | HC | Cx43 extracellular loop peptides | ↓mechanical hypersensitivity | Kaji et al., 2016 |
| Chemotherapy (bortezomib -induced peripheral neuropathy), rat | ↑ | Intraperitoneal injection of minocycline and CBX | GJC | Glial activation inhibitor and gap junction decoupler | — | Robinson and Dougherty, 2015 |
| Opioid intrathecal (i.t.) administration of morphine, rat | ↑ | Intrathecal injection of Gap26 | HC | Cx43 extracellular loop peptides | ↓morphine antinociceptive tolerance, ↓contralateral paw withdrawal frequency (PWF), while the ipsilateral PWF was not affected | Sheng et al., 2014 |
| Inflammation (unilateral carrageenan (CA) injection), rat | ↑ | Intrathecal injection of CBX or Gap26 | HC and GJC | Gap junction decoupler and Cx43 extracellular loop peptides | ↓pain hypersensitivity | Choi et al., 2017 |
| Bone Cancer Walker 256 tumor cells inoculation into the tibia, rat | p-Cx43↑ | Intrathecal injection of Gap26 | HC | Cx43 extracellular loop peptides | ↓mechanical allodynia | Hang et al., 2016 |
| Bone Cancer (intra-femoral inoculation of Lewis lung carcinoma cells), mouse | ↑ | Intrathecal injection of CBX | GJC | Gap junction decoupler | ↓pain hypersensitivity | Yang et al., 2018 |
| Breakthrough cancer pain (BTCP), mouse | Cx43 protein↑ | Intrathecal injection of Gap26 | HC | Cx43 extracellular loop peptides | ↓pain hypersensitivity | Li et al., 2017 |

↑ denotes upregulation; ↓ denotes downregulation; — denotes data unavailable.
In the TMZ-resistant GBM cells, Cx43 expression showed a significant upregulation. Studies suggested that an increase of functional EGFR expression activated the JNK-ERK1/2-AP-1 axis to upregulate Cx43 expression in the TMZ-resistant GBM cells (Munoz et al., 2014). TMZ-resistance was significantly reduced when Cx43 was suppressed by peptides targeting Cx43 channels or Cx43 C-terminal (Gielen et al., 2013; Murphy et al., 2016; Grek et al., 2018), which implies TMZ-resistance is highly dependent on Cx43 in gliomas.

Temozolomide resistance may be mediated by Cx43 via the mitochondrial apoptosis pathway (Gielen et al., 2013), or interactions between Cx43 carboxyl terminus and actin cytoskeleton (Crespin et al., 2010). GBM cells treated with a restored TMZ sensitivity (Gielen et al., 2013; Murphy et al., 2016). These results indicated that Cx43 carboxyl terminus confers TMZ-resistance in gliomas. Cx43 carboxyl terminus promotes tumor cell migration, and therefore may contribute to glioma invasion (Bates et al., 2007). However, another study showed that Cx43 can promote tumor invasion via a carboxyl terminus-independent manner, since Cx43 without carboxyl terminus can also increase migration (Crespin et al., 2010), which may be derived from connexin-based Ca^{2+} signaling and ATP release (Sin et al., 2016). Notably, utilizing Cx43 peptidomimetics as an adjuvant for TMZ resistance has been proposed (Grek et al., 2018).

Not only does the expression of Cx43 change, but its role may also vary with grades, stages, and locations of the tumors. Since many studies focused on Cx43 in gliomas, many new therapeutic targets have been proposed (e.g., Cx43 extracellular loop, Cx43 loop/tail interactions, Cx43 C-terminal) (Delvaeye et al., 2018). The diverse effects of these drugs are needed to testify to different conditions. In addition, specific drugs targeting Cx43 for varying glioma, may be a better solution based on the dynamic changes of Cx43.

**Cx43 IN BRAIN ISCHEMIA**

Brain ischemia is a leading cause of long-term disability or even mortality in adults. Insufficient blood flow, which fails to meet the high metabolic demands of the brain, will trigger the cascade reaction including tissue ischemia, reperfusion injury, inflammatory activity, leading to irreversible brain damage (Kim et al., 2018). Accumulating evidence suggests that astrocytic Cx43 expression is increased after hypoxia/ischemia injury and that Cx43 plays an important role in cell death and neuronal damage induced by cerebral ischemia (Davidson et al., 2012a,b, 2013, 2014; Ma et al., 2018). Ischemia/reperfusion injury and the following inflammatory activation can activate the astrocytic hemichannels via the increased extracellular Ca^{2+} and inflammatory factors released (Davidson et al., 2013). For instance, inflammatory factors just like IL-1β could reverse the inhibition of hemichannel activity caused by epidermal growth factor (EGF) (Morita et al., 2007); Cx43 hemichannels can...
also be triggered via p38 kinase by pro-inflammatory cytokines including IL-1β and TNF-α released by activated microglia (Retamal et al., 2007; Giaume et al., 2013). These abnormally opened hemichannels subsequently cause an uncontrolled release of ATP, glutamate, and an overload of Ca2+, leading to tissue excitotoxicity, amplification of the inflammation (Kim et al., 2018), and ultimately irreversible brain damage. The treatment of Cx43 mimetic peptide Gap26 leads to a reduction in both Cx43 expression and Cx43 hemichannels activity, which improve neurological function and reduce infarct volume (Li et al., 2015). According to this evidence, targeting to Cx43 might be a promising therapeutic strategy for brain ischemia, but more efforts are needed to develop specific inhibitors which can penetrate the blood-brain barrier.

**ASTROCYTES AND Cx43 IN CHRONIC PAIN**

Astrocytes are reactive in multiple types of conditioning-induced chronic pain, including peripheral and central nerve trauma, inflammation, chronic opioid exposure, etc. (Song and Zhao, 2001; Okada-Ogawa et al., 2009; Ren and Dubner, 2010; Chiang et al., 2012; Ji et al., 2013). Consistently, inhibiting the activity of astrocytes in the spinal cord can ameliorate chronic pain (Tsuda et al., 2011). Different from rapid activation of microglia, reactive astrocytes are usually found several days after injury and persist for a longer time (Mika et al., 2009; Old et al., 2015). This indicates that astrocytes might mainly contribute to the development and maintenance of chronic pain. The following mechanisms have been discussed in the astrocyte-mediated pain: (1) astrocytes can release multiple inflammatory mediators and neuromodulators, such as cytokines IL-1β, chemokines CCL2, and CXCL1; (2) a variety of receptors and transports, for example, ATP receptors P2XR and P2Y, glutamate transporter-1 (GLT-1), and glutamate and aspartic acid transporter (GLAST) can be activated in astrocytes; (3) the mitogen activated protein kinases (MAPKs) are also activated and further induce downstream signaling critical for pain; (4) reactive astrocytes also regulate the opening states of gap junctions or hemichannels, which further control the release of ATP, glutamate, and NAD+. These signaling pathways coordinate or interact with each other in response to pain. The role of Cx43 in pain is acknowledged by the study that Cx43/Cx30 deletion, instead of Cx30 single knockout, can alleviate the neuropathic pain developed between 4 and 8 weeks following spinal cord injury (Chen et al., 2012). Here, we will comprehensively discuss the role of Cx43 in chronic pain.

Studies have shown that Cx43 can act as a non-ligated hemichannel releasing small mediators or gliotransmitters, such as ATP and glutamate, into the extracellular environment (Bennett et al., 2003; D’hondt et al., 2014), which modulate synaptic transmission by directly interacting with nociceptive neurons, further contributing to pain. In addition, extracellular ATP also acts via its receptor P2X on non-neuronal cells, which contribute to pain by inducing the release of cytokines and chemokines.

Studies have shown that Cx43 can also regulate the expression or secretion of cytokines and chemokines in multiple systems. Although it is generally believed that hemichannels only allow passage of small molecules and ions, it has been reported that Cx43 can control the secretion of chemokine CXCL12 in bone marrow stromal cells (Schajnovitz et al., 2011). In the rat arthritis model, LPS treatment significantly enhanced Cx43 gene expression in rat fibroblast-like synoviocytes, whereas transfection of siCx43 inhibited the LPS-induced overexpression of pro-inflammatory cytokines and chemokines (Tsuchida et al., 2013). Furthermore, CBX (carboxenoxolone, a non-selective gap-junction inhibitor) reduces the increase of IL-1β and IL6 in cerebrospinal fluid caused by intrathecal injection of HIV1 gp120 (Spataro et al., 2004). The expression and secretion of cytokines or chemokines are up-regulated in TNF-α-activated astrocytes, which are important in the induction and maintenance of pain hypersensitivity (Gao et al., 2009; Huh et al., 2017). Our previous study has shown that TNF-α-induced CXCL1 and CCL2 release from astrocytes, were blocked by Cx43 small interfering RNA, CBX and 43Gap26 or 37,43Gap27 (two Cx43 mimetic peptides that blocks hemichannels), indicating that astrocytic Cx43 hemichannels are responsible for the release of the chemokines (Chen et al., 2014). Another study showed that intrathecal injection of 43Gap26 markedly attenuated mechanical allodynia in rat bone cancer model and reduced CXCL12 production from spinal dorsal horn in astrocytes (Hang et al., 2016). Although this evidence suggests that Cx43 hemichannels mediate the synthesis and secretion of chemokines, the mechanism remains unclear as chemokines are too large to directly efflux through the Cx43 hemichannels. One possible explanation is that activated calcium signaling contributes to CXCL12 secretion via the GTPase RalA (Schajnovitz et al., 2011). Another possibility is that an increase of purine induced by Cx43 may regulate the release of chemokines, based on the role of purinergic signaling in astrocytic release (Chen et al., 2014). Moreover, the Cx43 hemichannel may be hyperactive in pathological conditions, thereby causing chemokines to “leak” out of astrocytes through cytoskeletal changes (Cotrina et al., 2000).

The expression changes of Cx43 following pain is still inconclusive (Table 2). Multiple studies have shown that Cx43 is upregulated in astrocytes following nerve ligation and spinal cord injury, and that inhibition of Cx43 can attenuate pain hypersensitivity (Wu et al., 2011; Chen et al., 2012, 2014, 2018; Shen et al., 2014; Neumann et al., 2015; Robinson and Dougherty, 2015; Choi et al., 2016; Hang et al., 2016; Kaji et al., 2016; Mao et al., 2017a,b; Wang and Sun, 2017; Yang et al., 2018). On the contrary, few studies showed that a decrease of Cx43 following nerve injury could contribute to pain hypersensitivity (Xu et al., 2014; Morioka et al., 2015; Zhang et al., 2016). Interestingly, in a mouse model of breakthrough cancer pain, Cx43 protein level is upregulated while phosphorylation of Cx43 (p-Cx43) is downregulated (Li et al., 2017). The conflict might come from distinct pain conditions or models. Additionally, it might not be the Cx43 expression level alone that determines the enhanced or attenuated function of hemichannels or gap junctions, because even in the pain model with decreased Cx43
expression, inhibition of CX43 function can still relieve pain (Xu et al., 2014).

Studies have shown that CX43 can be highly regulated by astrocytic inflammatory mediators, growth factors, or receptors. TNF-α and IL-1β, inflammatory mediators produced by astrocytes in pain, can modulate the expression of CX43 (Morioka et al., 2015; Choi et al., 2017). For example, TNF decreases CX43 expression in naïve mice, which can be reversed by the TNF inhibitor (Morioka et al., 2015). Reactive astrocytes also lead to an increase in the basic fibroblast growth factor (bFGF or FGF-2) in the late phase following nerve injury. bFGF increases the expression of CX43 and enhances intercellular communication of CX43 gap junction in cardiac fibroblasts (Doble and Kardami, 1995), though the study of the role of bFGF in astrocytic CX43 is lacking. In addition, the sigma-1 receptor activated by astrocytes in both peripheral and central neuropathy, could also modulate the activation of CX43. The increase in CX43 expression can be reversed by a sigma-1 receptor blocker (Choi et al., 2016).

Increasing evidence has shown that mitogen-activated protein kinases (MAPKs) can also regulate the opening states of CX43 channels in astrocytes. Activation of MAPKs family members contribute to pain sensitization. For instance, extracellular signal-regulated kinases (ERKs) is significantly upregulated in astrocytes when animals were injected with complete Freund's adjuvant (CFA), a drug inducing inflammation and pain (Weyerbacher et al., 2010). Phosphorylation of C-Jun N-terminal kinases (JNKs), predominantly JNK-1, is observed in spinal astrocytes in a persistent pain condition (Gao et al., 2010). MAPKs lead to a closure of CX43 gap junction and hemichannels, while MAPK phosphatase make CX43 preferentially open (Kim et al., 1999; Goodenough and Paul, 2003; Solan and Lampe, 2005). Notably, phosphorylation and dephosphorylation events not only regulate the gating of channels, but also the trafficking and assembly of connexins (Ribeiro-Rodrigues et al., 2017), indicating the complicated effects of MAPKs on CX43.

Though the interaction between CX43 and molecules involved in pain offers a complicated feedback loop in pain development and maintenance, based on the current studies, strategies to suppress the function of CX43 may be a robust approach for pain relief (Wu et al., 2011; Chen et al., 2012, 2014; Shen et al., 2014; Xu et al., 2014; Neumann et al., 2015; Robinson and Dougherty, 2015; Choi et al., 2016; Hang et al., 2016; Kaji et al., 2016; Mao et al., 2017a,b; Wang and Sun, 2017; Yang et al., 2018).

CX43 might function as hemichannels or a gap junction, which has not been clearly characterized in every single study (Tables 1, 2). A non-selective gap-junction inhibitor carbenoxolone (CBX) can reduces neuropathic pain (Wang et al., 2014), supporting the ideas that CX43 can function as a gap junction. On the other hand, studies proposed a model in which CX43 can function as a non-junctional hemichannel to release mediators such as ATP and glutamate (Bennett et al., 2003; D’hondt et al., 2014). There are a few ways to distinguish hemichannels and gap junctions. For example, when used for short incubation time or at a low concentration, peptide 5, a mimetic of CX43, can only inhibit hemichannels, but when applied for a long incubation time or at a long concentration, can attenuate both hemichannels and gap junctions (Choi et al., 2016; Mao et al., 2017a). Another approach to distinguish CX43 gap junction and hemichannels are using the dyes uptaken. Lucifer yellow, only permeable to the gap junction, while ethidium bromide is considered exclusively uptaken by hemichannels. The diffusion rates of these dyes will differentiate hemichannel and gap junction. Interestingly, a peptide derived from the cytoplasmic loop of CX43 termed Gap19 can specifically function in CX43 hemichannels while not affecting gap junctions (Abudara et al., 2014). In addition, La3+ can specifically block hemichannels rather than gap junctions. Typically, the use of these drugs is accompanied by other blockers or dyes, however, thus far no drugs that only target to CX43 are available.

The enriched expression of CX43 and wide distribution of astrocytes in the brain and spinal cord might explain the complicated phenotypes observed in animals with CX43 manipulation. Though changes of either ATP, glutamate, or Ca2+ can be detected when CX43 is manipulated, it is hard to tell how each molecule contributes to the system since (1) few studies have systematically tested all changes of these molecules; (2) not only local signaling is affected by these small molecules.

CONCLUSION AND PERSPECTIVES

Astrocytes modulate extrasynaptic or synaptic milieu to further enhance or dampen electrochemical signaling propagating in neurons. As the major connexin altered following nerve injury, CX43 can be regulated by multiple signals under pathological conditions, which in turn, modulate several downstream signals critical for neuronal activity, and further contribute to a variety of CNS disorders, including pain. So far, up to 21 phosphorylation sites have been reported in CX43 (Pogoda et al., 2016), indicating a complex post-translational modification. Further studies might be necessary to characterize how these phosphorylation sites contribute to specific CNS disorders. Of note, besides connexin hemichannels, pannexins is also detectable in astrocytes (Garre et al., 2010). Pannexin-1, like CX43, can also be inhibited by the non-selective gap-junction blocker CBX (Garre et al., 2010). Therefore, the role of Pannexin-1 in pain control could be an interesting topic to explore. In addition, how connexins interact with pannexins and the signaling pathways mediated by connexins or pannexins need further investigation. Selective manipulation of connexins might be a potential therapeutic approach in some CNS disorders.

AUTHOR CONTRIBUTIONS

LX and TY wrote and drafted the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

FUNDING

This study was supported by The National Key Research and Development Program of China (2017YFA0104704 and
The Natural Science Foundation of China (31872773, 81701127, and 81671220), The Natural Science Foundation of JiangSu University (BK20170446 and BK20181460), The Natural Science Foundation of the JiangSu Higher Education Institutions of China (17KJA180009), the Jilin Scientific and Technological Development Program (201601010777C), and the Jilin Provincial School Joint Construction Special Project (SXGJQY2017-13).

REFERENCES

Abudara, V., Bechberger, J., Freitas-Andrade, M., De Bock, M., Wang, N., Bultyynck, G., et al. (2014). The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front. Cell. Neurosci. 8:306. doi: 10.3389/fncel.2014.00306

Almad, A. A., Doreswamy, A., Gross, S. K., Richard, J. P., Huo, Y., Haughey, N., et al. (2016). Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia 64, 1154ñ1169. doi: 10.1002/glia.22989

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., and Jones, E. (2011). Alzheimer’s disease. Lancet 377, 1019ñ1031. doi: 10.1016/S0140-6736(10)61349-9

Bates, D. C., Sin, W. C., Aftab, Q., and Naus, C. C. (2007). Connexin43 enhances Cx43 hemichannels and gap junction channels. J. Cell Sci. 120, 137ñ146. doi: 10.1242/jcs.133553

Bennett, M. V. L., Contreras, J. E., Bukauskas, F. F., and Sáez, J. C. (2003). New roles for astrocytes: gap junction hemichannels have something to communicate. Trends Neurosci. 26, 610ñ617. doi: 10.1016/j.tins.2003.09.008

Cabezas, R., Avila, M., González, J., El-Bachá, R. S., Báez, E., García-Segura, L. M., et al. (2012). Astrocytic β(2)-adrenergic receptors modulate connexin 43 expression leading to the induction of below-level mechanical allodynia in spinal cord injured mice. Brain 137, 2193ñ2209. doi: 10.1093/brain/awu140

Chen, G., Park, C. K., Xie, R. G., Berta, T., and Sáez, J. C. (2012). Connexin43 confers temozolomide resistance in human glioma cells. J. Neurosci. 32, 2419ñ2431. doi: 10.1523/JNEUROSCI.3623-08.2009

Chiang, C.-Y., Sesso, B. J., and Dostrovsky, J. O. (2012). Role of astrocytes in pain. Neurochem. Res. 37, 2419ñ2431. doi: 10.1007/s11064-012-0801-6

Choi, H.-S., Roh, D.-H., Yoon, S.-Y., Kwon, S.-G., Choi, S.-R., Kang, S.-Y., et al. (2017). The role of spinal interleukin-1β and astrocyte connexin 43 in the development of mirror-image pain in an inflammatory pain model. Exp. Neurol. 287, 1ñ13. doi: 10.1016/j.expneurol.2016.10.012

Cotrina, M. L., Lin, J. H., López-García, J. C., Naus, C. C., and Nedergraad, M. (2000). ATP-mediated glia signaling. J. Neurosci. 20, 2835ñ2844. doi: 10.1523/JNEUROSCI.20-08-02835.2000

Crespín, S., Bechberger, J., Mesnil, M., Naus, C. C., and Sin, W. C. (2010). The carboxy-terminal tail of connexin43 gap junction protein is sufficient to mediate cytoskeleton changes in human glioma cells. J. Cell. Biochem. 109, 589ñ597. doi: 10.1002/jcb.22554
Grek, C. L., Sheng, Z., Naus, C. C., Sin, W. C., Gourdie, R. G., and Ghatnekar, G. G. (2018). Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapies. *Curr. Opin. Pharmacol.* 31, 78–99. doi: 10.1016/j.coph.2018.05.002

Hang, L.-H., Li, S.-N., Luo, H., Shu, W.-W., Mao, Z.-M., Chen, Y.-F., et al. (2016). Connexin43 mediates CXCCL12 production from spinal dorsal horn to maintain bone cancer pain in rats. *Neurochem. Res.* 41, 1200–1208. doi: 10.1007/s11064-015-1815-7

Hawad, G., Bendertoum, D., Rousseau, G., and Baroudi, G. (2010). Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. *Pflugers Arch.* 460, 583–592. doi: 10.1007/s00424-010-0849-6

Hirayama, Y., and Koizumi, S. (2018). Astrocytes and ischemic tolerance. *Neurosci.* Res. 126, 53–59. doi: 10.1016/j.neures.2017.11.013

Huh, Y., Ji, R.-R., and Chen, G. (2017). Neuroinflammation, bone marrow stem cells, and chronic pain. *Front. Immunol.* 8:1014. doi: 10.3389/fimmu.2017.01014

Ji, R.-R., Berta, T., and Nedergaard, M. (2013). Glia and pain: is chronic pain a gliopathy? *Pain* 154(Suppl.), S10–28. doi: 10.1016/j.pain.2013.06.022

Johansen, D., Cruciani, V., Sundset, R., Ytrehus, K., and Mikalsen, S.-O. (2011). Ischemia induces closure of gap junctional channels and opening of hemichannels in heart-derived cells and tissue. *Cell. Physiol. Biochem.* 28, 103–114. doi: 10.1159/00031719

Kaji, K., Shinoda, M., Honda, K., Unno, S., Shimizu, N., and Iwata, K. (2016). Connexin 43 contributes to ectopic orofacial pain following inferior alveolar nerve injury. *Mol. Pain.* 12, 1–12. doi: 10.1177/1744806916637004

Kim, D. Y., Kam, Y., Koo, S. K., and Joe, C. O. (1999). Gating connexin 43 channels reconstituted in lipid vesicles by mitogen-activated protein kinase phosphorylation. *J. Biol. Chem.* 274, 5581–5587. doi: 10.1074/jbc.274.9.5581

Kim, Y., Davidson, J. O., Green, C. R., Nicholson, L. F. B., O’Carroll, S. J., and Joe, C. O. (2018). Expression changes of microRNA-1 and its targets connexin 43 and brain-derived neurotrophic factor at sites of amyloid plaques in Alzheimer’s disease. *Brain Res.* 717, 173–178. doi: 10.1016/j.brainres.2015.01.045

Old, E. A., Clark, A. K., and Malcangio, M. (2015). The role of glia in the spinal cord in neuropathic and inflammatory pain. *Handb. Exp. Pharmacol.* 227, 145–170. doi: 10.1007/978-3-662-46450-2_8

Orellana, J. A., Retamal, M. A., Alcayaga, J., Verdugo, C. A., Bultynck, G., Leybaert, L., Sáez, P. J., and Steblin, J. (2016). Role of astroglial hemichannels and pannexons in memory and neurodegenerative diseases. *Front. Integr. Neurosci.* 10:26. doi: 10.3389/fnint.2016.00026

Pascual, O. (2005). Astrocytic purinergic signaling coordinates synaptic networks. *Science* (80-.): 310, 113–116. doi: 10.1126/science.1116916

Pogoda, K., Kameritsch, P., Retamal, M. A., and Vega, J. L. (2016). Regulation of gap junction channels and hemichannels by phosphorylation and redox changes: a revision. *BMC Cell Biol.* 17:110. doi: 10.1186/s12860-016-0099-3

Rash, J. E., Yasumura, T., Davidson, K. G., Furman, C. S., Dudek, F. E., and Nagy, J. I. (2001a). Identification of cells expressing Cx43, Cx30, Cx26, Cx32 and Cx36 in nervous systems in pain. *Front. Cell. Neurosci.* 5:18. doi: 10.3389/neuro.02.018.2011

Ren, K., and Dubner, R. (2010). Interactions between the immune and nervous systems in pain. *Nat. Med.* 16, 1267–1276. doi: 10.1038/nm.2234

Ren, R., Zhang, L., and Wang, M. (2018). Specific deletion connexin43 in astrocyte precursors/progenitor/presenilin1 mice. *Neurosci. Lett.* 694, 154–160. doi: 10.1016/j.neulet.2017.11.005

Rash, J. E., Yasumura, T., Dudek, F. E., and Nagy, J. I. (2001b). Cell-specific expression of connexins and evidence of restricted gap junctional coupling between glial cells and between neurons. *J. Neurosci.* 21, 1983–2000. doi: 10.1523/JNEUROSCI.2458-00.2001

Renalt, M. A., Alcayaga, J., Verdugo, C. A., Bulytnyck, G., Leybaert, L., Sáez, P. J., et al. (2014). Opening of pannexin- and connexin-based channels increases the excitability of nodose ganglion sensory neurons. *Front. Cell. Neurosci.* 8:158. doi: 10.3389/fncel.2014.00158

Retamal, M. A., Hofer, N., Palacios-Prado, N., Ezan, P., Saez, P. J., Saez, J. C., et al. (2007). Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia. *J. Neurosci.* 27, 13781–13792. doi: 10.1523/JNEUROSCI.4202-07.2007

Xing et al.  Astrocytic Connexin 43 in CNS Disorders
Sin, W. C., Aftab, Q., Bechberger, J. F., Leung, J. H., Chen, H., and Naus, Scott, C. A., Tattersall, D., O'Toole, E. A., and Kelsell, D. P. (2012). Connexins in Rodríguez, J. J., Olabarria, M., Chvatal, A., and Verkhratsky, A. (2009). Astroglia in Song, P., and Zhao, Z. Q. (2001). The involvement of glial cells in the development Sontheimer, H. (2015). Brain cancer: tumour cells on neighbourhood watch. Robinson, C. R., and Dougherty, P. M. (2015). Spinal astrocyte gap junction and Wang, H., Cao, Y., Chiang, C.-Y., Dostrovsky, J. O., and Sessle, B. J. (2014). The gap junction blocker carbenoxolone attenuates nociceptive behavior and mediatory dorsal horn central sensitization induced by partial infraorbital nerve transection in rats. Pain 155, 429–433. doi: 10.1016/j.pain.2013.11.004 Wang, H., and Sun, X. (2017). Carbon monoxide-releasing molecule-2 inhibits connexin 43-hemichannel activity in spinal cord astrocytes to attenuate neuropathic pain. J. Mol. Neurosci. 63, 58–69. doi: 10.1007/s12031-017-0957-2 Wang, L., Peng, Y., Peng, J., Shao, M., Ma, L., Zhu, Z., et al. (2018). Tramadol attenuates the sensitivity of globlostoma to temolozolomide through the suppression of Cx43-mediated gap junction intercellular communication. Int. J. Onco. 52, 295–304. doi: 10.3892/ijo.2017.4188 Wang, N., De Vuyyst, E., Ponsaerts, R., Boengler, K., Palacios-Prado, N., Wauman, J., et al. (2013). Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res. Cardiol. 108:309. doi: 10.1007/s00395-012-0309-x Wang, Y., Wu, Z., Liu, X., and Fu, Q. (2013). Lamina gastrodin ameliorates Parkinson's disease by downregulating connexin 43. Mol. Med. Rep. 8, 585–590. doi: 10.3892/mmr.2013.1535 Weyerbacher, A. R., Xu, Q., Tamasdan, C., Shin, S. I., and Inturrisi, C. E. (2010). N-Methyl-D-aspartate receptor (NMDAR) independent maintenance of inflammatory pain. Pain 148, 237–246. doi: 10.1016/j.pain.2009.11.003 Wu, X. F., Liu, W. T., Liu, Y. P., Huang, Z. J., Zhang, Y. K., and Song, X. J. (2011). Reopening of ATP-sensitive potassium channels reduces neuropathic pain and regulates astroglial gap junctions in the rat spinal cord. Pain 152, 2605–2615. doi: 10.1016/j.pain.2011.08.003 Xu, H., Gu, S., Riquelme, M. A., Burra, S., Callaway, D., Cheng, H., et al. (2015). Connexin 43 channels are essential for normal bone structure and osteocyte viability. J. Bone Miner. Res. 30, 436–448. doi: 10.1002/jbmr.2374 Xu, Q., Cheong, Y.-K., He, S.-Q., Tiwari, V., Liu, J., Wang, Y., et al. (2014). Suppression of spinal connexin 43 expression attenuates mechanical hypersensitivity in rats after an L5 spinal nerve injury. Neurosci. Lett. 566, 194–199. doi: 10.1016/j.neulet.2014.03.004 Yang, C., Rahimpour, S., Yu, A. C. H., Lonser, R. R., and Zhuang, Z. (2013). Regulation and dysregulation of astrocyte activation and implications in tumor formation. Cell. Mol. Life Sci. 70, 4201–4211. doi: 10.1007/s00018-013-1274-8 Yang, H., Yan, H., Li, X., Liu, J., Cao, S., Huang, B., et al. (2018). Inhibition of connexin 43 and phosphorylated NR2B in spinal astrocytes attenuates bone cancer pain in mice. Front. Cell. Neurosci. 12:129. doi: 10.3389/fncel.2018.00129 Yi, C., Ezan, P., Fernández, P., Schmitz, J., Saez, J. C., Gaume, C., et al. (2017a). Inhibition of glial hemichannels by boldine treatment reduces neuronal suffering in a murine model of Alzheimer's disease. GLIA 65, 1607–1625. doi: 10.1002/glia.23182 Yi, C., Koulkoff, A., and Gaume, C. (2017b). Astroglial connexins as a therapeutic target for Alzheimer's disease. Curr. Pharm. Des. 23, 4985–4968. doi: 10.2174/138161282366171004151215 Yi, C., Mei, X., Ezan, P., Mato, S., Matias, L., Gaume, C., et al. (2016). Astroglial connexin43 contributes to neuronal suffering in a mouse model of Alzheimer's disease. Cell Death Differ. 23, 1691–1701. doi: 10.1038/cdd.2016.63 Zhang, F. F., Morioka, N., Kitamura, T., Fujii, S., Miyauchi, K., Nakamura, Y., et al. (2016). Lycopene ameliorates neuropathic pain by upregulating spinal astrocytic connexin 43 expression. Life Sci. 155, 116–122. doi: 10.1016/j.lfs.2016.05.021 Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2019 Xing, Yang, Cui and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.